GAM
VPHM

Gotham Asset Management’s VIROPHARMA INC VPHM Stock Holding History

Gotham Asset Management’s Portfolio VPHM Stock Details VPHM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-6,987
Closed -$200K – 1007
2013
Q2 		$200K Buy
+6,987
New +$184K 0.01% 825

Other funds holding VPHM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Gotham Asset Management's VPHM Position: Q3 2013 in Review

Gotham Asset Management sold out of VIROPHARMA INC (VPHM) in Q3 2013, closing a stake of 6,987 shares — an estimated $200K sold.

Gotham Asset Management first reported a position in VPHM in Q2 2013 and held it in 1 quarter. The position peaked at $200K in Q2 2013. 191 funds tracked by Wall St. Rank hold VPHM as of Q3 2013.

  • Gotham Asset Management reported no remaining VIROPHARMA INC position as of Q3 2013 after selling out during the quarter.
  • Gotham Asset Management sold 6,987 VIROPHARMA INC shares in Q3 2013, an estimated $200K.
  • Gotham Asset Management first reported a position in VIROPHARMA INC in Q2 2013 and held it in 1 quarter.
  • Gotham Asset Management's VIROPHARMA INC position peaked at $200K in Q2 2013.
  • 191 funds tracked by Wall St. Rank held VIROPHARMA INC as of Q3 2013.

Based on Gotham Asset Management's 13F filing for Q3 2013, filed 14 Nov 2013.